Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback